Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Metheny-Barlow, LJ; Flynn, B; van Gijssel, HE; Marrogi, A; Gerwin, BI
   Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma - Antiproliferative effects in vitro and tumorigenicstimulation in vivo
   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
   
   L.J. Metheny-Barlow et al., "Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma - Antiproliferative effects in vitro and tumorigenicstimulation in vivo", AM J RESP C, 24(6), 2001, pp. 694-702
2. Marrogi, A; Pass, HI; Khan, M; Metheny-Barlow, LJ; Harris, CC; Gerwin, BI
   Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): In vitro antiproliferative effects of a COX-2 inhibitor
   CANCER RESEARCH
   
   A. Marrogi et al., "Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): In vitro antiproliferative effects of a COX-2 inhibitor", CANCER RES, 60(14), 2000, pp. 3696-3700
3. SCHWARZENBERGER P; HARRISON L; WEINACKER A; MARROGI A; BYRNE P; RAMESH R; THEODOSSIOU C; GAUMER R; SUMMER W; FREEMAN SM; KOLLS JK
   THE TREATMENT OF MALIGNANT MESOTHELIOMA WITH A GENE MODIFIED CANCER CELL-LINE - A PHASE-I STUDY
   Human gene therapy
   
   P. Schwarzenberger et al., "THE TREATMENT OF MALIGNANT MESOTHELIOMA WITH A GENE MODIFIED CANCER CELL-LINE - A PHASE-I STUDY", Human gene therapy, 9(17), 1998, pp. 2641-2649
4. NARAYAN A; JI WZ; ZHANG XY; MARROGI A; GRAFF JR; BAYLIN SB; EHRLICH M
   HYPOMETHYLATION OF PERICENTROMERIC DNA IN BREAST ADENOCARCINOMAS
   International journal of cancer
   
   A. Narayan et al., "HYPOMETHYLATION OF PERICENTROMERIC DNA IN BREAST ADENOCARCINOMAS", International journal of cancer, 77(6), 1998, pp. 833-838
5. FREEMAN SM; MCCUNE C; ROBINSON W; ABBOUD CN; ABRAHAM GN; ANGEL C; MARROGI A
   THE TREATMENT OF OVARIAN-CANCER WITH A GENE MODIFIED CANCER VACCINE -A PHASE-I STUDY
   Human gene therapy
   
   S.M. Freeman et al., "THE TREATMENT OF OVARIAN-CANCER WITH A GENE MODIFIED CANCER VACCINE -A PHASE-I STUDY", Human gene therapy, 6(7), 1995, pp. 927-939
6. WHARTENBY KA; ABRAHAM GN; CALABRESI PA; ABBOUD CN; CALABRESI P; MARROGI A; FREEMAN SM
   GENE-MODIFIED CELLS FOR THE TREATMENT OF CANCER
   Pharmacology & therapeutics
   
   K.A. Whartenby et al., "GENE-MODIFIED CELLS FOR THE TREATMENT OF CANCER", Pharmacology & therapeutics, 66(1), 1995, pp. 175-190
7. DEVITO J; FUNG H; MEROGI A; BOH E; COCKERELL C; STEWART K; FREEMAN S; MARROGI A
   BORRELIA-BURGDORFERI IS NOT A CONTRIBUTING FACTOR IN PATHOGENESIS OF MORPHEA SCLERODERMA LICHEN-SCLEROSUS-ET-ATROPHICUS - A POLYMERASE CHAIN-REACTION (PCR) STUDY OF 36 CASES
   Journal of investigative dermatology
   
   J. Devito et al., "BORRELIA-BURGDORFERI IS NOT A CONTRIBUTING FACTOR IN PATHOGENESIS OF MORPHEA SCLERODERMA LICHEN-SCLEROSUS-ET-ATROPHICUS - A POLYMERASE CHAIN-REACTION (PCR) STUDY OF 36 CASES", Journal of investigative dermatology, 104(4), 1995, pp. 654-654